Stringent Complete Response (Scr) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (Ndmm) Treated With Carfilzomib (Cfz), Lenalidomide (Len), And Dexamethasone (Dex).

8011 Background: Combination treatment (tx) with CFZ, LEN, and DEX (CRd) is well tolerated and highly active in NDMM. In a phase 1/2 study, CRd provided rapid reduction of disease by 68% after cycle (C) 1 and 94% ≥partial response (PR) at a median of 8C, including 65% ≥very good PR and 53% ≥near CR (nCR), which improved to 79% ≥nCR after C12 (ASH 2011, Abstr 631). Here, we examine the clinical significance of the response rates with longer follow-up. Methods: Pts with NDMM were treated in 28-day (d) C with CFZ 20–36 mg/m2 IV (d1, 2, 8, 9, 15, 16), LEN 25 mg PO (d1–21) and DEX 40/20 mg PO weekly (C1–4/5–8). After C4, autologous stem cell transplant (ASCT) candidates achieving ≥PR could collect stem cells but then continued CRd with the option to proceed to ASCT. After C8, pts received CRd maintenance, using the last tolerated doses, with LEN/DEX at the same schedule but a modified CFZ schedule (d1, 2, 15, 16). Response was assessed by IMWG criteria plus nCR. Results: As of Nov 30, 2011, median follow-up wa...